Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA)

被引:0
|
作者
Giovanni DiPaolo
Cecilia Jimenez-Moreno
Nikoletta Nikolenko
Antonio Atalaia
Darren G. Monckton
Michela Guglieri
Hanns Lochmüller
机构
[1] Keel University School of Medicine,John Walton Muscular Dystrophy Research Centre
[2] Newcastle University,Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences
[3] University of Glasgow,undefined
[4] Newcastle Upon Tyne Hospitals NHS Foundation Trust,undefined
来源
Journal of Neurology | 2017年 / 264卷
关键词
Myotonic dystrophy; Falls; DM1; Balance;
D O I
暂无
中图分类号
学科分类号
摘要
Myotonic dystrophy type 1 (DM1) is not characterised by ataxia per se; however, DM1 and ataxia patients show similar disturbances in movement coordination often experiencing walking and balance difficulties, although caused by different underlying pathologies. This study aims to investigate the use of a scale previously described for the assessment and rating of ataxia (SARA) with the hypothesis that it could have utility in DM1 patients as a measure of disease severity and risk of falling. Data from 54 DM1 patients were pulled from the PHENO-DM1 natural history study for analysis. Mean SARA score in the DM1 population was 5.45 relative to the maximum score of eight. A flooring effect (score 0) was observed in mild cases within the sample. Inter-rater and test–retest reliability was high with intraclass coefficients (ICC) of 0.983 and 1.00, respectively. Internal consistency was acceptable as indicated by a Cronbach’s alpha of 0.761. Component analysis revealed two principle components. SARA correlated with: (1) all measures of muscle function tested, including quantitative muscle testing of ankle dorsiflexion (r = −0.584*), the 6 min walk test (r = −0.739*), 10 m walk test (r = 0.741*), and the nine hole peg test (r = 0.602*) and (2) measures of disease severity/burden, such as MIRS (r = 0.718*), MDHI (r = 0.483*), and DM1-Activ (r = −0.749*) (*p < 0.001). The SARA score was predicted by an interaction between modal CTG repeat length and age at sampling (r = 0.678, p = 0.003). A score of eight or above predicted the use of a walking aid with a sensitivity of 100% and a specificity of 85.7%. We suggest that further research is warranted to ascertain whether SARA or components of SARA are useful outcome measures for clinical trials in DM1. As a tool, it can be used for gathering information about disease severity/burden and helping to identify patients in need of a walking aid, and can potentially be applied in both research and healthcare settings.
引用
收藏
页码:701 / 708
页数:7
相关论文
共 50 条
  • [41] Significant impact of behavioral and cognitive impairment on quality of life in patients with myotonic dystrophy type 1
    Rakocevic-Stojanovic, V.
    Peric, S.
    Madzarevic, R.
    Dobricic, V.
    Ralic, V.
    Ilic, V.
    Basta, I.
    Nikolic, A.
    Stefanova, E.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 126 : 76 - 81
  • [42] Dyslexia and cognitive impairment in adult patients with myotonic dystrophy type 1: a clinical prospective analysis
    K. Gutschmidt
    S. Wenninger
    F. Montagnese
    B. Schoser
    Journal of Neurology, 2021, 268 : 484 - 492
  • [43] Fuchs' Endothelial Corneal Dystrophy in Patients With Myotonic Dystrophy, Type 1
    Winkler, Nelson S.
    Milone, Margherita
    Martinez-Thompson, Jennifer M.
    Raja, Harish
    Aleff, Ross A.
    Patel, Sanjay V.
    Fautsch, Michael P.
    Wieben, Eric D.
    Baratz, Keith H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (07) : 3053 - 3057
  • [44] TRANSCRANIAL SONOGRAPHY IN PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
    Peric, Stojan
    Pavlovic, Aleksandra
    Ralic, Vesna
    Dobricic, Valerija
    Basta, Ivana
    Lavrnic, Dragana
    Stojanovic, Vidosava Rakocevic
    MUSCLE & NERVE, 2014, 50 (02) : 278 - 282
  • [45] Metabolic syndrome in patients with myotonic dystrophy type 1
    Vujnic, M.
    Peric, S.
    Dobricic, V.
    Ralic, V.
    Novakovic, I.
    Stojanovic, V. Rakocevic
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 528 - 528
  • [46] Aerobic training in patients with myotonic dystrophy type 1
    Orngreen, MC
    Olsen, DB
    Vissing, J
    ANNALS OF NEUROLOGY, 2005, 57 (05) : 754 - 757
  • [47] OCCURRENCE OF CANCER IN PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
    Hameed, Bilal
    DiCapua, Daniel
    MUSCLE & NERVE, 2021, 64 : S73 - S73
  • [48] Mitochondrial dysfunction in myotonic dystrophy type 1 patients
    Di Leo, V.
    Lawless, C.
    Roussel, M-P.
    Gorman, G.
    Russell, O.
    Tuppen, H.
    Duchesne, E.
    Vincent, A.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S129 - S129
  • [49] Muscle phenotype in patients with myotonic dystrophy type 1
    Andersen, Grete
    Orngreen, Mette C.
    Preisler, Nicolai
    Colding-Jorgensen, Eskild
    Clausen, Torben
    Duno, Morten
    Jeppesen, Tina D.
    Vissing, John
    MUSCLE & NERVE, 2013, 47 (03) : 409 - 415
  • [50] Psychological characteristics of patients with myotonic dystrophy type 1
    Bertrand, J. A.
    Jean, S.
    Laberge, L.
    Gagnon, C.
    Mathieu, J.
    Gagnon, J. F.
    Richer, L.
    ACTA NEUROLOGICA SCANDINAVICA, 2015, 132 (01): : 49 - 58